Cargando…

Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment

Detalles Bibliográficos
Autores principales:	Richardson, Paul G., Corbacioglu, Selim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055222/ https://www.ncbi.nlm.nih.gov/pubmed/32132522 http://dx.doi.org/10.1038/s41408-020-0286-5

Ejemplares similares

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
por: Richardson, Paul, et al.
Publicado: (2019)

A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
por: Corbacioglu, Selim, et al.
Publicado: (2022)

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
por: Richardson, Paul, et al.
Publicado: (2019)

Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients
por: Corbacioglu, Selim, et al.
Publicado: (2020)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study
por: Mohty, Mohamad, et al.
Publicado: (2022)

Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome
por: Kernan, Nancy A., et al.
Publicado: (2018)

Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer
por: Corbacioglu, Selim, et al.
Publicado: (2023)

Defibrotide for hepatic veno-occlusive disease
Publicado: (2021)

Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019)

Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
por: Richardson, Paul G., et al.
Publicado: (2020)

Defibrotide in the treatment of hepatic veno-occlusive disease
por: Fulgenzi, Alessandro, et al.
Publicado: (2016)

Pooled analysis of Day 100 survival for defibrotide‐treated patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation
por: Richardson, Paul G., et al.
Publicado: (2020)

A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting
por: Tappe, William, et al.
Publicado: (2020)

Erratum to “A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting”
Publicado: (2020)

Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide
por: Kong, Seom Gim, et al.
Publicado: (2022)

Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
por: Mavrikou, Ioulia, et al.
Publicado: (2023)

Gemtuzumab ozogamicin: Various toxicities: 2 case reports
Publicado: (2017)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
por: Pautas, Cécile, et al.
Publicado: (2021)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome
por: Liu, Zhenli, et al.
Publicado: (2022)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Imaging features of hepatic sinusoidal obstruction syndrome or veno-occlusive disease in children
por: Bohte, Anneloes E., et al.
Publicado: (2021)

P1355: VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES OF DEFIBROTIDE-TREATED ADULT PATIENTS FROM THE DEFIFRANCE STUDY
por: Mohty, M., et al.
Publicado: (2022)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
por: Zaytsev, Daniil, et al.
Publicado: (2020)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
por: Kurimoto, M, et al.
Publicado: (2013)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
por: Yu, Bo, et al.
Publicado: (2019)

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
por: Russell-Smith, T. Alexander, et al.
Publicado: (2021)

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group
por: Mohty, Mohamad, et al.
Publicado: (2019)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
por: Fatobene, Giancarlo, et al.
Publicado: (2021)

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)
por: Mohty, M, et al.
Publicado: (2015)

Two Cases of Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Thioguanine Treatment for Acute Lymphoblastic Leukemia
por: Gruhn, Bernd, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vkhvnt58o94uukk4fueg2m9qgd